Physician profile
Ruby Thomas
NPI 1497705032
$722.85
in general payments reported to CMS, 2019-2025
12 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.90 · 2020: $32.90 · 2022: $123 · 2023: $133 · 2024: $229 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $117.30 | 2023-2024 | Invega Sustenna, Invega Trinza, Invega |
| Supernus Pharmaceuticals, INC. | $103.20 | 2022-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $94.09 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $80.12 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Sunovion Pharmaceuticals INC. | $72.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $59.99 | 2024-2025 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.12 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $56.45 | 2022-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $32.90 | 2020 | |
| Lundbeck LLC | $16.76 | 2024 | Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $15.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.12 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.